Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4NIH 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 38Lymphoma 38Lung Neoplasms 25Ovarian Neoplasms 24Melanoma 23Neoplasm Metastasis 21Hematologic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Fallopian Tube Neoplasms 19Breast Neoplasms 18Prostatic Neoplasms 17Glioma 17Sarcoma 14Carcinoma, Renal Cell 14Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Lymphoma, Non-Hodgkin 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 11Glioblastoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Medulloblastoma 10Wilms Tumor 9Sarcoma, Ewing 9Rhabdomyosarcoma 9Rhabdoid Tumor 9

Interventions

pembrolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Diffusion Tensor Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Turcot syndrome × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡